Mary Thistle is the Chief of Staff of the Bill & Melinda Gates Medical Research Institute. She has more than 25 years of experience in finance, strategy and business development functions across different therapeutic areas, including gene therapy. Prior to joining the Bill & Melinda Gates Medical Research Institute, Ms. Thistle was Chief Operating Officer of Dimension Therapeutics Inc. At Dimension, she oversaw the company’s Series B financing and initial public offering, expanded the pipeline through strategic business development transactions, and led the sale of the company to Ultragenyx Pharmaceutical Inc. Prior, Ms. Thistle was the Senior Vice President, Business Development at Cubist Pharmaceuticals, where she was responsible for multiple acquisitions and assisted in the sale to Merck. Ms. Thistle held senior level positions at ViaCell Inc. in finance, operations and business development, and then served as Senior Vice President, Business Development at PerkinElmer after ViaCell was acquired. Ms. Thistle began her career in finance as a Certified Public Accountant. Ms. Thistle also serves on the Board of Directors of Enterome SA and is a graduate of the Women in Bio Boardroom Ready program.